SCHEMBL6988795

SCHEMBL6988795

NC(=S)CCN1C(=O)c2ccccc2C1=O

nearest known ligand 0.62

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
ALDH1A1 P00352 5/20 0.52
MAPT P10636 1/20 0.52
GLS O94925 1/20 0.52
KMT2A Q03164 3/20 0.51
GAA P10253 1/20 0.51
HPGD P15428 1/20 0.51
HSD17B10 Q99714 1/20 0.51
POLB P06746 1/20 0.50
SMN1; SMN2 Q16637 2/20 0.49
MEN1 O00255 1/20 0.48
L3MBTL1 Q9Y468 1/20 0.48
HDAC8 Q9BY41 3/20 0.47
HDAC3 O15379 2/20 0.47
HDAC4 P56524 2/20 0.47
HDAC1 Q13547 2/20 0.47
HDAC7 Q8WUI4 2/20 0.47
HDAC2 Q92769 2/20 0.47
HDAC10 Q969S8 2/20 0.47
HDAC11 Q96DB2 2/20 0.47
HDAC6 Q9UBN7 2/20 0.47

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL6994876 0.89 ALDH1A1 (0.54) ALDH1A1MAPTKMT2AHSD17B10SMN1; SMN2
SCHEMBL8686938 0.88 HDAC8 (0.59) ALDH1A1KMT2AHPGDSMN1; SMN2L3MBTL1
SCHEMBL8686967 0.86 HDAC8 (0.61) ALDH1A1KMT2AHPGDSMN1; SMN2L3MBTL1
SCHEMBL29441539 0.83 ALDH1A1 (0.57) ALDH1A1GLSKMT2AGAAHPGD
SCHEMBL1477933 0.83 ALDH1A1 (0.57) ALDH1A1GLSKMT2AGAAHPGD
SCHEMBL19368443 0.81 GLS (0.52) ALDH1A1GLSKMT2AGAAHPGD
SCHEMBL1358387 0.81 CA12 (0.60) ALDH1A1MAPTKMT2APOLBMEN1
SCHEMBL29842074 0.81 CA12 (0.60) ALDH1A1MAPTKMT2APOLBMEN1
Hydrochloric Acid SCHEMBL6945018 0.80 ALDH1A1 (0.50) ALDH1A1GLSKMT2AGAAHPGD
SCHEMBL14594063 0.79 KMT2A (0.60) ALDH1A1GLSKMT2AGAAHPGD

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 12 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-2753604-B1 PDE10 MODULATORS HOFFMANN LA ROCHE (CH) 2015-08-19 EP disclosed
US-8772510-B2 PDE10 modulators HOFFMANN-LA ROCHE INC. (US) 2014-07-08 US disclosed
EP-2574607-A1 PDE10 modulators F. Hoffmann-La Roche AG (CH) 2013-04-03 EP disclosed
WO-2013034506-A1 PDE10 MODULATORS F. HOFFMANN-LA ROCHE AG (CH) 2013-03-14 WO disclosed
US-20130059833-A1 PDE10 MODULATORS F. HOFFMANN-LA ROCHE AG (CH) 2013-03-07 US disclosed
EP-0709386-B1 FUSED BENZAZEPINE DERIVATIVE AND PHARMACEUTICAL COMPOSITION CONTAINING THE SAME YAMANOUCHI PHARMA CO LTD (JP) 2003-05-07 EP disclosed
EP-1097920-A1 Intermediate for condensed benzazepine derivatives YAMANOUCHI PHARMACEUTICAL CO. LTD. (JP) 2001-05-09 EP disclosed
US-5834499-A TREATING GASTROINTESTINAL DISORDERS YAMANOUCHI PHARMACEUTICAL CO., LTD. (JP) 1998-11-10 US disclosed
CN-1040210-C Fused benzazepine derivative and pharmaceutical composition containing the same YAMANOUCHI PHARMA CO LTD (JP) 1998-10-14 CN disclosed
US-5723606-A Condensed benzazepine derivative and pharmaceutical composition thereof YAMANOUCHI PHARMACEUTICAL CO., LTD. (JP) 1998-03-03 US disclosed
CN-1143364-A 5-HT3 receptor agonist, novel thiazole derivative, and intermediate thereof YAMANOUCHI PHARMA CO LTD (JP) 1997-02-19 CN disclosed
EP-0749966-A1 5-HT 3 RECEPTOR AGONIST, NOVEL THIAZOLE DERIVATIVE, AND INTERMEDIATE THEREFOR YAMANOUCHI PHARMACEUTICAL CO. LTD. (JP) 1996-12-27 EP disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20130059833-A1 PDE10 MODULATORS PDE10A, PDE5A, PDE2A ALDH1A1 775/4885MAPT 1196/4885GLS 1230/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.